Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. HERBESSER R200 CAPSULES 200 MG [SIN10061P]

HERBESSER R200 CAPSULES 200 MG [SIN10061P]

Active ingredients: HERBESSER R200 CAPSULES 200 MG

Last updated 26 October 2025

On this page

Product Info
INDICATIONS
DOSAGE AND ADMINISTRATION
CONTRAINDICATIONS (HERBESSER R is contraindicated in the following patients.)

Product Info

HERBESSER R200 CAPSULES 200 MG

[SIN10061P]

Product information

Active Ingredient and Strength

DILTIAZEM HCL - 200 MG

Dosage Form

CAPSULE

Manufacturer and Country

PT MITSUBISHI TANABE PHARMA INDONESIA - INDONESIA REP OF
MITSUBISHI TANABE PHARMA FACTORY LTD - JAPAN

Registration Number

SIN10061P

Licence Holder

MITSUBISHI TANABE PHARMA SINGAPORE PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

C08DB01

INDICATIONS

  • Essential hypertension (mild to moderate)

  • Angina pectoris, variant angina pectoris

DOSAGE AND ADMINISTRATION

  • Essential hypertension (mild to moderate)
    Usually, for adults, I00 mg to 200 mg of diltiazem hydrochloride is orally administered once daily. The dosage may be adjusted according to the patient’s age and symptoms.

  • Angina pectoris, variant angina pectoris
    Usually, for adults, 100 mg of Diltiazem hydrochloride is orally administered once daily. If the effect is insufficient, the dosage may be increased to 200 mg once daily.

CONTRAINDICATIONS (HERBESSER R is contraindicated in the following patients.)

  1. Patients with severe congestive heart cardiac failure [Symptoms of cardiac failure may be aggravated].

  2. Patients with second or third degree atrioventricular block or sick sinus syndrome (persistent sinus bradycardia) (less than 50 beats/ minute), sinus arrest, sinoatrial block, etc.) [Depression of cardiac stimulation and cardiac conduction may occur excessively].

  3. Patients with a history of hypersensitivity to any of the ingredients of this product.

  4. Pregnant women or women who may possibly be pregnant [See “Use during pregnancy, Delivery or lactation” section – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information].

  5. Patients receiving ivabradine hydrochloride. [See “Drug Interactions” section – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.]